CPC C07K 16/2872 (2013.01) [C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 2 Claims |
1. A method for treating a neurodegenerative disorder in a subject in which aberrant PrPc activity is involved, comprising: administering to the subject a pharmaceutically effective amount of an antibody or an antigen-binding fragment comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein the VH domain comprises:
a VH CDR 1 having the amino acid sequence of SEQ ID NO: 5;
a VH CDR2 having the amino acid sequence of SEQ ID NO: 6; and
a VH CDR3 having the amino acid sequence of SEQ ID NO: 7; and
the VL domain comprises:
a VL CDR1 having the amino acid sequence of SEQ ID NO: 14;
a VL CDR2 having the amino acid sequence of SEQ ID NO: 15; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 16; and
wherein the neurodegenerative disorder is one of: Alzheimer's Disease, disease associated with misfolded PrP, Creutzfeldt-Jakob Disease, Gerstmann-Sträussler-Schenker Disease, Fatal Familial Insomnia, bovine spongiform encephalopathy, scrapie, chronic wasting disease, transmissible mink encephalopathy, and feline spongiform encephalopathy.
|